Developing carbon nanotube vectors - in vitro biocompatibility

COLL 47

Valerie C. Moore, Valerie.Moore@uth.tmc.edu1, Melinda Lackey1, Jared L. Hudson, jlhudson@rice.edu2, Paul Cherukuri, cheru@rice.edu3, James. M. Tour, tour@rice.edu2, and Jodie L. Conyers1. (1) Department of Internal Medicine, University of Texas Health Science Center at Houston, 6770 Bertner Avenue THI C964A, Houston, TX 77030, (2) Department of Chemistry and Center for Nanoscale Science and Technology, Rice University, MS 222, 6100 Main Street, Houston, TX 77005, (3) Department of Chemistry, Carbon Nanotechnology Laboratory, Rice University, 6100 Main Street, MS 100, Houston, TX 77005
Carbon nanotubes are a unique candidate for the foundation of a multifunctional nanovector where the targeting, imaging, and therapeutic agents can be customized for optimal efficacy depending on patient or disease. The first step in development of a carbon nanotube vector is, of course, biocompatibility. This study focuses on PEGylated nanotubes through both covalent sidewall PEGylation and noncovalent Pluronic wrapping. To assess biocompatibility a variety of assays including LDH, MTT, and Annexin V were preformed using several cell lines. The nanotube formulation biocompatibility is concentration dependent with most formulation being nontoxic at reasonable dose levels. Also an investigation of biocompatibility dependence on nanotube length will be discussed.
 

Advances in Nanomedicine
8:30 AM-12:20 PM, Sunday, 10 September 2006 Sir Francis Drake -- Monterey/Cypress Rooms, Oral

Division of Colloid & Surface Chemistry

The 232nd ACS National Meeting, San Francisco, CA, September 10-14, 2006